Plasma lipidomic biomarker analysis reveals distinct lipid changes in vascular dementia
- PMID: 32670502
- PMCID: PMC7334482
- DOI: 10.1016/j.csbj.2020.06.001
Plasma lipidomic biomarker analysis reveals distinct lipid changes in vascular dementia
Abstract
Vascular dementia (VaD) is a complex neurocognitive disorder secondary to a variety of cerebrovascular lesions. Numerous studies have shown that lipid metabolism is involved in the pathobiology of the disease. We examined the plasma lipid profiles in VaD, with the expectation of identifying reliable lipid biomarkers for VaD. 49 VaD patients and 48 healthy controls were recruited from Bankstown-Lidcombe Hospital in Sydney, Australia. Lipids were extracted by single phase 1-butanol/methanol, and untargeted analysis was performed by liquid chromatography coupled-mass spectrometry (LC-MS/MS). Univariate analysis of variance was used to examine the differences in lipid classes and individual lipids between VaD and control groups. In an independent sample of 161 subjects from the Older Australian Twins Study (OATS), elastic net penalization for the generalized linear model (Glmnet) and Random Forest were applied to the lipid levels to subcategorise the sample into vascular cognitive impairment and controls. Most lipids belonging to the classes of ceramides (Cer), cholesterol esters (ChE) and phospholipids were significantly lower in VaD plasma, while glycerides were elevated compared to controls. Levels of ChE, Cer and the two lipid classes together achieved the best accuracy in discriminating VaD from controls, with more than 80% accuracy. The probable VaD group in the OATS sample predicted by the lipid levels showed greater impairment in most cognitive domains, especially attention and processing speed and executive function from controls but did not differ in white matter hyperintensities and DTI measures. As a conclusion, plasma lipids levels, in particular Cer and ChE, are abnormal in VaD and may help discriminate them from healthy controls. Understanding the basis of these differences may provide insights into the pathobiology of VaD.
Keywords: Lipids; Plasma biomarkers; Small vessel disease; Vascular dementia.
© 2020 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Wallin A., Gottfries C.G., Karlsson I., Svennerholm L. Decreased myelin lipids in alzheimer's disease and vascular dementia. Acta Neurol Scand. 1989;80:319–323. - PubMed
-
- Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H. Vascular dementia: diagnostic criteria for research studies. Report of the ninds-airen international workshop. Neurology. 1993;43:250–260. - PubMed
-
- Sachdev P.S., Lammel A., Trollor J.N., Lee T., Wright M.J., Ames D. A comprehensive neuropsychiatric study of elderly twins: the older australian twins study. Twin Res Hum Genet. 2009;12:573–582. - PubMed
-
- Baykara E., Gesierich B., Adam R., Tuladhar A.M., Biesbroek J.M., Koek H.L. A novel imaging marker for small vessel disease based on skeletonization of white matter tracts and diffusion histograms. Ann Neurol. 2016;80:581–592. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials